Creating a universal vaccine to protect against all types of influenza
Development of vaccination strategies to elicit broadly protective immunity against influenza
This study is working on a new flu vaccine that could protect you for a long time against different types of the flu virus, even the ones that might cause big outbreaks, by helping your immune system recognize important parts of the virus.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Rockefeller University NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-10878418 on NIH RePORTER |
What this research studies
This research focuses on developing a universal influenza vaccine that can provide long-lasting protection against various strains of the virus, including those that may cause pandemics. The approach involves targeting specific parts of the influenza virus, particularly the hemagglutinin (HA) protein, which is crucial for the virus's ability to infect cells. By designing new vaccine components that stimulate the immune system to recognize and respond to conserved regions of the HA protein, the research aims to enhance the body's ability to fight off different influenza strains effectively.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals who are at higher risk for influenza complications, such as the elderly, young children, and those with underlying health conditions.
Not a fit: Patients who are not at risk for influenza or those who have already been vaccinated with current strain-specific vaccines may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a vaccine that protects against multiple strains of influenza, reducing the risk of future pandemics and improving public health.
How similar studies have performed: Other research has shown promise in developing universal vaccines for influenza, indicating that this approach has potential based on previous findings.
Where this research is happening
New York, United States
- Rockefeller University — New York, United States (Active)
Researchers
- Principal investigator: Ravetch, Jeffrey Victor — Rockefeller University
- Study coordinator: Ravetch, Jeffrey Victor
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.